Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: A prospective study on multicenter basis

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 177-182

  Kim, Seung Jin ^a   Shiba, Eiichi ^a   Kobayashi, Tetsuro ^a   Yayoi, Eiji ^b   Furukawa, Junkou ^b   Takatsuka, Yuichi ^c   Shin, Eisei ^c   Koyama, Hiroki ^d   Inaji, Hideo ^d   Takai, Shin Ichiro ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Osaka Teishin Hospital   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; PROTEINASE; TAMOXIFEN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 2642705008     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Duffy, M. J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metastasis, 10: 145-155, 1992.
2. Schmitt, M., Janicke, F., and Graeff, H. Tumor-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul. Fibrinolysis, 1: 695-702, 1990.
3. Ganesh, S., Sier, C. F. M., Griffioen, G., Vloedgraven, H. J. M., Boer, A., Welvaart, K., van de Velde, C. J. H., van Krieken, J. H. J. M., Verheijen, J. H., Lamers, C. B. H. W., and Verspaget, H. W. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54: 4065-4071, 1994.
4. Nekarda, H., Schmitt, M., Ulm, K., Wenninger, A., Vogelsang, H., Becker, K., Roder, J. D., Fink, U., and Siewert, J. R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res., 54: 2900-2907, 1994.
5. Yonemura, Y., Nojima, N., Kaji, M., Fujimura, T., Itoh, H., Ninomiya, I., Miyazaki, I., Endo, Y., and Sasaki, T. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer (Phila.), 76: 941-953, 1995.
6. Gandolfo, G. M., Conti, L., and Vercillo, M. Fibrinolysis components as prognostic marker in breast cancer and colorectal carcinoma. Anticancer Res., 16: 2155-2159, 1996.
7. Cho, J. Y., Chung, H. C., Noh, S. H., Roh, J. K., Min, J. S., and Kim, B. S. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer (Phila.), 79: 878-883, 1997.
8. Duffy, M. J. Urokinase-type plasminogen activator and malignancy. Fibrinolysis, 7: 295-302, 1993.
9. Schmitt, M., Janicke, F., Moniwa, N., Chucholowski, N., Pache, L., and Graeff, H. Tumor-associated urokinase type plasminogen activator biological and clinical significance. Biol. Chem. Hoppe-Seyler, 373: 611-622, 1992.
10. Duffy, M. J., Reilly, D., O'Sullivan, C., O'Higgins, N., Fennelly, J. J., and Andreasen, P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50: 6827-6829, 1990.
11. Janicke, F., Schmitt, M., Hafter, R., Hollrieder, A., Babic, R., Ulm, K., Gossner, W., and Graeff, H. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4: 69-78, 1990.
12. Foekens, J. A., Schmitt, M., van Putten, W. L. J., Peters, H. A., Bontenbal, M., Janicke, F., and Klijn, J. G. M. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res., 52: 6101-6105, 1992.
13. Grondahl-Hansen, J., Christensen, I. J., Rosenquist, C., Brunner, N., Mouridsen, H. T., Dano, K., and Blichert-Toft, M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53: 2513-2521, 1993.
14. Janicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Hofler, H., and Graeff H. Urokinase (uPA), and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat., 24: 195-208, 1993.
15. Duffy, M. J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J. J., and Lijnen, H. R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res., 48: 1348-1349, 1988.
16. Duffy, M. J., Duggan, C., Maguire, T., Mulcahy, K., Elvin, P., McDermott, E., Fennelly, J. J., and O'Higgins, N. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme Protein, 49: 85-93, 1996.
17. McGuire, W. L., Tandon, A. K., Allred, D. C., Chamness, G. C., Ravdin, P. M., and Clark, G. M. Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer (Phila.), 70 (Suppl. 6): 1775-1781, 1992.
18. Isola, J., Visakorpi, T., Holli, K., and Kallioniemi, O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer Inst. (Bethesda), 84: 1109-1114, 1992.
19. Wong, W. W., Vijayakumar, S., and Weichselbaum, R. R. Prognostic indicators in node-negative early stage breast cancer. Am. J. Med., 92: 539-548, 1992.
20. O'Reilly, S. M., Camplejohn, R. S., Barnes, D. M., Millis, R. R., Rubens, R. D., and Richards, M. A. Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J. Clin. Oncol., 8: 2040-2046, 1990.
21. Fox, S. B., Leek, R. D., Smith, K., Hollyer, J., Greenall, M., and Harris, A. L. Tumor angiogenesis in node-negative breast carcinomas: relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res. Treat., 29: 109-116, 1994.
22. Ranby, M., Bergsdorf, N., Nilsson, T., Mellbring, G., Winblad, B., and Bucht, G. Age dependence of tissue plasminogen activator concentrations in plasma as studied by an improved enzyme-linked immunosorbent assay. Clin. Chem., 32: 160-165, 1986.
23. Duffy, M. J., Reilly, D., McDermott, E., O'Higgins, N., Fennelly, J. J., and Andreasen, P. A. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer (Phila.), 74: 2276-2280, 1994.
24. Fersis, N., Kaufmann, M., Kramer, M. D., Wittmann, G., Wallwiener, D., and Bastert, G. Prognostic significance of plasminogen activator inhibitor-1 (PAI-1) in primary breast cancer. Geburtsh. Frauenheilkd., 56: 28-34, 1996.
25. Yamashita, J., Ogawa, M., and Sakai, K. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery (St. Louis), 117: 601-608, 1995.
26. Janicke, F., Pache, L., Schmitt, M., Ulm, K., Thomssen, C., Prechtl, A., and Graeff, H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res., 54: 2527-2530, 1994.
27. Blasi, F. Surface receptors for urokinase plasminogen activator. Fibrinolysis, 2: 73-84, 1988.
28. Moller, L. B. Structure and function of the urokinase receptor. Blood Coagul. Fibrinolysis, 4: 293-303, 1993.
29. Blasi, F., Conese, M., Moller, L. B., Pedersen, N., Cavallaro, U., Cubellis, M. V., Fazioli, F., Hernandez-Marrero, L., Limongi, P., Munoz-Canoves, P., Resnati, M., Riittinen, L., Sidenius, N., Soravia, E., Soria, M. R., Stoppelli, M. P., Talarico, D., Teesalu, T., and Valcamonica, S. The urokinase receptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis, 8 (Suppl. 1): 182-188, 1994.
30. Dano, K., Behrendt, N., Brunner, N., Ellis, V., Ploug, M., and Pyke, C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis, 8 (Suppl. 1): 189-203, 1994.
31. Pyke, C., Graem, N., Ralfkiaer, E., Ronne, E., Hoyer-Hansen, G., Brunner, N., and Dano, K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res., 53: 1911-1915, 1993.
32. Bianchi, E., Cohen, R. L., Thor, A. T., Todd, R. F., Mizukami, I. F., Lawrence, D. A., Ljung, B. M., Shuman, M. A., and Smith, H. S. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res., 54: 861-866, 1994.
33. Carriero, M. V., Franco, P., Vecchio, S. D., Massa, O., Botti, G., D'Aiuto, G., Patrizia Stoppelli, M., and Salvatore, M. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res., 54: 5445-5454, 1994.
34. Kim, S. J., Shiba, E., Taguchi, T., Inoue, T., Tanji, Y., Kimoto, Y., Izukura, M., and Takai, S. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Res., 17: 1373-1378, 1997.
35. Reilly, D., Christensen, L., Duch, M., Nolan, N., Duffy, M. J., and Andreasen, P. A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer, 50: 208-214, 1992.
36. Janicke, F., Schmitt, M., and Graeff, H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemostasis, 17: 303-312, 1991.
37. Camiolo, S. M., Markus, G., and Piver, M. S. Plasminogen activator content of gynecological tumors and their metastasis. Gynecol. Oncol., 26: 364-373, 1987.
38. Markus, G., Camiolo, S. M., Kohga, S., Madeja, J. M., and Mittelman, A. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors. Cancer Res., 43: 5517-5525, 1983.
39. Duffy, M. J., O'Grady, P., Simon, J., Rose, M., and Lijnen, H. R. Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors. J. Natl. Cancer Inst. (Bethesda), 77: 621-623, 1986.
40. Rella, C., Coviello, M., Quaranta, M., and Paradiso, A. Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer. Thromb. Res., 69: 209-220, 1993.
41. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment for early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339: 1-15, 1992.
42. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment for early breast cancer by hormonal, cytotoxic, or immune therpy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339: 71-85, 1992.
43. Goldhirsh, A., Wood, W. C., Senn, H-J., Glick, J. H., and Gelber, R. D. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J. Natl. Cancer Inst. (Bethesda), 87: 1441-1445, 1995.